Erlotinib Completed Phase 1 Trials for Extrahepatic Bile Duct Cancer / Small Intestine Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas / Periampullary Adenocarcinoma / Liver Cancer Treatment

CompletedTreatment1 IdentifierTitleDrugs
NCT00987766Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
NCT00266097Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
NCT00565487Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
NCT00243854Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
NCT00614653Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
NCT00735306Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
NCT00885066Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
NCT00925769ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer